Navigation Links
Tekturna Infographic Released by d’Oliveira & Associates Imparts Potential Side Effects of Blood Pressure Drug
Date:4/18/2013

(PRWEB) April 18, 2013

Tekturna (aliskiren), produced by Novartis, is a once-daily pill used to treat high blood pressure (hypertension) and is the first “Renin Inhibitor” drug that regulates the renin enzyme in the kidney. This process assists by narrowing the blood vessels and removes water from the bloodstream in order to improve overall circulation (i). In 2011, the FDA determined that aliskiren products had been prescribed over 2.4 million times to over 451,000 patients in the United States (ii). According to the National Institutes of Health, Novartis has marketed aliskiren under the following names: Amturnide, TekAmlo, Tekturna, TekturnaHCT, and Valturna (iii).

According to a press release from Novartis, the company stopped its ALTITUDE medical study in December of 2011 because Tekturna increased the risk of nonfatal stroke, kidney complications, hyperkalemia, and hypotension in patients with Type-2 diabetes. The study was conducted on the part of Novartis in an effort to expand the uses of Tekturna due to the “product profitability in 2011 was negative (iv).” Additional adverse events were recorded by The Institute for Safe Medication Practices in there October of 2012 issue of Quarter Watch which stated that 100 cases of angioedema (swelling) were reported by Tekturna patients in the first quarter of 2012 (v). The same publication also detailed other cases that included one report of death, two reports labeled life threatening, 15 reports of hospitalization, and a final total of 237 Tekturna adverse event reports, “more than any other blood pressure medication (v).”

The infographic issued by d’Oliveira & Associates provides general information on Tekturna as well as lists possible side effects. Side effects allegedly connected to the high blood pressure drug may include: kidney complications, hyperkalemia, angioedema, heart attack, stroke, and/or birth defects. Visit the Tekturna page and view the infographic here: Tekturna Infographic

If you or a loved one has suffered any injuries after taking Tekturna, you may want to file a claim. You should find the best Tekturna lawyer because you may only have one chance at justice. A personal injury lawyer familiar with this blood pressure drug may be able to provide you with important personal and legal advice. d’Oliveira & Associates, P.C., is working with some of the more experienced dangerous drug lawyers who are handling these cases. Please contact the law offices of d’Oliveira & Associates, P.C. at 1-800-992-6878 or fill out a contact form for a free legal consultation.

Sources:
(i) http://www.tekturna.com/info/treating-high-blood-pressure.jsp
(ii) http://www.fda.gov/Drugs/DrugSafety/ucm300889.htm
(iii) http://www.nlm.nih.gov/medlineplus/druginfo/meds/a607039.html
(iv) http://www.novartis.com/newsroom/media-releases/en/2011/1572562.shtml
(v) http://www.ismp.org/NEWSLETTERS/ACUTECARE/showarticle.asp?id=32

Read the full story at http://www.prweb.com/releases/2013/4/prweb10644073.htm.


'/>"/>
Source: PRWeb
Copyright©2012 Vocus, Inc.
All rights reserved

Related medicine news :

1. St Jude Retreats Releases New Infographic Which Reports Consequences of Drunk Driving
2. d'Oliveira & Associates Issues New Infographic on Xarelto Providing Current FDA and Medical Study Information
3. d'Oliveira & Associates Releases New Byetta Infographic on Potential Kidney and Pancreas Health Risks Associated with the Drug
4. IHC Specialty Benefits Releases an Affordable Care Act Infographic to Help Customers Determine Health Insurance Rebates
5. d'Oliveira & Associates Releases Zimmer Knee Infographic Providing Important Safety Information on High-Flex Knees
6. Loyola University New Orleans Presents a History of Nursing in its New Infographic: Nursing Evolution
7. Law Firm Issues Biomet Hip Infographic Warning Consumers About the Dangers of Biomet Hip Implants
8. d'Oliveira & Associates Releases Fresenius Infographic about the FDA Recall of NaturaLyte and GranuFlo
9. d’Oliveira & Associates Releases Mirena IUD Infographic Describing Bayer’s Deceptive Mirena Simple Style Campaign
10. MacGregor & Collins, LLP Releases New California DUI Infographic
11. Get New Patients, INC Releases New Infographic titled 'Are Negative Reviews Killing Your Medical Practice?"
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:4/24/2017)... New York, NY (PRWEB) , ... April 24, ... ... students in 72 countries clearly shows that over the last decade, student well-being ... have ticked all the boxes of formal education, join the Islamic State to ...
(Date:4/24/2017)... ... April 24, 2017 , ... Miami Periodontist ... the 2017 Oral Reconstruction Foundation’s 2017 Symposium on Tissue Regeneration and Implant Dentistry ... present its annual Global Symposium at the Fontainebleau Hotel located in Miami Beach, ...
(Date:4/24/2017)... ... , ... A 2-in-1 bottleless water appliance provides both purified ... Texas, here are the ways in which this technology can benefit dental offices: ... fresh, oxygenated water, with both cold and hot options. , Convenience for Dentists ...
(Date:4/22/2017)... Philadelphia, PA (PRWEB) , ... ... ... Small Business Administration of Eastern Pennsylvania has named PROSHRED® Security of ... Pennsylvania-native Ginny Heron-Doerr, PROSHRED® Philadelphia specializes in providing information destruction ...
(Date:4/21/2017)... (PRWEB) , ... April 21, 2017 , ... An April ... of a pair of ancient teeth, which reveal a great deal about prehistoric ice-age ... a sharp stone may have been used to remove decayed dental matter, and that ...
Breaking Medicine News(10 mins):
(Date:4/20/2017)... Sweden , April 20, 2017 ... NEVPF) ("NeuroVive") today announced positive preclinical results ... preclinical compound for non-alcoholic steatohepatitis (NASH), in ... NV556 has previously shown ... NASH model. Today, NeuroVive,s scientists present novel ...
(Date:4/19/2017)...  IRIDEX Corporation (Nasdaq: IRIX ) today ... first quarter 2017 after the close of trading on ... host a corresponding conference call beginning at 2:30 p.m. ... in listening to the conference call may do so ... 326-3030 for international callers, using conference ID: 92158987.  A ...
(Date:4/19/2017)... 2017  Sorrento Therapeutics, Inc. (NASDAQ: ... developing new treatments for cancer and other unmet ... previously announced underwritten public offering of 23,625,084 shares ... price of $2.00 per share, before deducting underwriting ... by Sorrento.  The net proceeds to Sorrento from ...
Breaking Medicine Technology: